COMPARATIVE SAFETY OF BIOLOGIC AND TARGETED SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS FOR CARDIOVASCULAR AND CANCER OUTCOMES IN RHEUMATOID ARTHRITIS

被引：0
|
作者：
Sendaydiego, X. [1 ]
Gold, L. [2 ]
Lee, J. [3 ]
Goulabchand, R. [4 ]
Hughes, G. [5 ]
Pioro, M. [5 ]
Andrews, J. [5 ]
Makris, U. [6 ]
Suri, P. [7 ]
Jarvik, J. [8 ]
Sparks, J. [9 ]
Singh, S. [10 ]
Singh, N. [5 ]
机构：
[1] Univ Washington, Med, Internal Med Residency, Seattle, WA USA
[2] Univ Washington, Ctr Musculoskeletal Disorders, Clin Learning Evidence & Res CLEAR, Radiol, Seattle, WA USA
[3] Univ Michigan, Med Rheumatol, Ann Arbor, MI USA
[4] CHU Nimes Univ Montpellier, Med, Nimes, France
[5] Univ Washington, Med Rheumatol, Seattle, WA USA
[6] Univ Texas SouthWestern, Med Rheumatol, Dallas, TX USA
[7] Univ Washington, Ctr Musculoskeletal Disorders, Clin Learning Evidence & Res CLEAR, Rehabil Med, Seattle, WA USA
[8] Univ Washington, Radiol, Hlth Serv Res Ctr, Seattle, WA USA
[9] Brigham & Womens Hosp, Med Rheumatol, Boston, MA USA
[10] Univ Calif San Diego, Med Gastroenterol, La Jolla, CA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
基金：
美国国家卫生研究院;
关键词：
Cardiovascular disease; Rheumatoid arthritis; Disease-modifying Drugs (DMARDs);
D O I：
10.1136/annrheumdis-2023-eular.2462
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0398
引用
收藏
页码：1382 / 1383
页数：2
相关论文
共 50 条
  • [21] Decision Aid-Led Tapering of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Qualitative Study
    Lee, Jungyeon
    Barber, Claire E. H.
    Jung, Michelle
    Kaminska, Elzbieta
    Bansback, Nick
    Richards, Dawn
    Proulx, Laurie
    Rebutoc, Ann
    Hazlewood, Glen S.
    JOURNAL OF RHEUMATOLOGY, 2024, 51 (12) : 1077 - 1083
  • [22] RENAL FUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING BIOLOGIC OR TARGETED SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS WITHIN THE AUSTRALIAN OPAL DATASET
    Littlejohn, Geoff
    Bird, Paul
    Griffith, Hedley
    INTERNAL MEDICINE JOURNAL, 2021, 51 : 27 - 27
  • [23] Frailty and Risk of Serious Infections in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted-Synthetic Disease-Modifying Antirheumatic Drugs
    Singh, Namrata
    Gold, Laura S.
    Lee, Jiha
    Wysham, Katherine D.
    Andrews, James S.
    Makris, Una E.
    England, Bryant R.
    George, Michael D.
    Baker, Joshua F.
    Jarvik, Jeffrey
    Heagerty, Patrick J.
    Singh, Siddharth
    ARTHRITIS CARE & RESEARCH, 2024, 76 (05) : 627 - 635
  • [24] Safety of biological disease-modifying antirheumatic drugs in rheumatoid arthritis
    Martinez-Mugica, Cristina
    Salgueiro, Esther
    FARMACIA HOSPITALARIA, 2022, 46 (01) : 15 - 20
  • [25] What happened to rheumatoid arthritis patients who stopped biologic or targeted synthetic disease modifying antirheumatic therapy?
    Burkard, Theresa
    Vallejo-Yaguee, Enriqueta
    Huegle, Thomas
    Finckh, Axel
    Burden, Andrea M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 397 - 398
  • [26] Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia
    Fletcher, Ashley
    Lassere, Marissa
    March, Lyn
    Hill, Catherine
    Barrett, Claire
    Carroll, Graeme
    Buchbinder, Rachelle
    RHEUMATOLOGY, 2022, 61 (10) : 3939 - 3951
  • [27] PREDICTION OF SUSTAINED BIOLOGIC AND TARGETED SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUG FREE REMISSION IN RHEUMATOID ARTHRITIS PATIENTS
    Burkard, T.
    Williams, R. D.
    Vallejo-Yague, E.
    Hugle, T.
    Finkch, A.
    Kyburz, D.
    Burden, A. M.
    OSTEOPOROSIS INTERNATIONAL, 2021, 32 (SUPPL 1) : S333 - S333
  • [28] The exposure to biologic and targeted synthetic disease-modifying antirheumatic drugs in pregnancy and lactation
    Goralczyk, Alicja
    Kolossa, Katarzyna
    Waszczak-Jeka, Marzena
    Adamczak, Rafal
    Jeka, Slawomir
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2020, 37 (03): : 306 - 312
  • [29] TREATMENT ADHERENCE TO CONVENTIONAL AND BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Feldman, C. H.
    Lii, J.
    Gopalakrishnan, C.
    Franklin, J. M.
    Kim, S. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 526 - 526
  • [30] ANNUAL TREATMENT COST OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS
    Hosseini, R.
    Brown, L. M.
    Fleming, M.
    Rodriguez-Monguio, R.
    Seoane-Vazquez, E.
    VALUE IN HEALTH, 2024, 27 (06) : S110 - S110
12345